Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Teleflex to Promote the Rise of the Vascular Access Specialist and Demonstrate Arrow® Brand Products at the Association for Vascular Access® (AVA) 2016 Congress in Orlando, FL

Teleflex Incorporated
Posted on: 16 Sep 16

Teleflex Incorporated (NYSE: TFX), a leading provider of medical technologies for critical care and surgery, will focus on the rise of the vascular access specialist with its vascular access technologies and new educational platform at the 30th Annual Scientific Meeting of the Association for Vascular Access (AVA), in Orlando, Florida, to be held September 16-19, 2016.

The rise of the vascular access specialist has become a part of the mission statement for Teleflex’s Arrow® Vascular Access business. We believe in striving for zero complications to become reality within vascular access, and we believe that expertise in vascular access can help achieve this goal. Teleflex supports this goal with education, advocating scope of practice expansion and innovative technology. At AVA this year, we will be showcasing our educational and vascular products to support the rise of the vascular access specialist.

Teleflex will be unveiling the Teleflex Academy, a new online clinical education platform. The booth educational experience for the Teleflex Academy at this year’s AVA will focus on every aspect of vascular access, inspiring confidence, enhancing skills and enabling clinicians to make an even bigger difference in their patient’s lives. Teleflex believes that quality education is the first step in fostering the expansion of skills and helping to shape clinical practice.

Teleflex is excited to launch the Arrow® Midline with Chlorag+ard® Technology, adding to the family of antithrombogenic and antimicrobial protected catheters.1,2

The company will offer its popular Vascular Access Procedural Cadaver Lab onsite, training on many different vascular access procedures. Teleflex will also have clinical education activities at its booth, where models will be used to demonstrate the full range of the company’s vascular access devices.

At the breakfast symposium, “Rising to the Challenge: How Vascular Access Specialists Started Placing CVCs,” attendees will be educated on the importance of the evolution of the vascular access specialist. This course highlights the experiences of clinicians who have made the journey to expand their roles to place central venous catheters, and describes the clinical process and materials needed to develop a vascular access team.

The platinum showcase symposium, “Locking the Lumen…Consider the Solutions!” will review why given today’s medical reimbursement risks, facilities must explore all opportunities to reduce potential vascular access complications. Locking solutions could provide an additional layer of protection when used in conjunction with proven protected catheter technology. The presentation will address catheter colonization, intraluminal colonization and how locking solutions and protected catheters address these.

The dinner symposium, “Strategy or Risk: the Use of Midline Catheters”, will focus on the recent popularity of Midline catheters, the role of a Midline, and how technology could be the key to ensuring Midline success.

“The ‘Right Line, Right Patient, Right Time™’ has been at the center of our Vascular business model for many years and we continue to be the market leader in this philosophy,” said Jay White, president and general manager of the Vascular Access Division. “We have developed first class vascular educational programs for vascular access clinicians. We are proud to provide clinicians with solutions such as Chlorag+ard® Technology which protects the catheter surface beyond initial insertion in addition to tools to treat their patients with the best possible care. We look forward to launching these clinical education and vascular products at this year’s AVA meeting.”

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Chlorag + ard, Deknatel, Hudson RCI, LMA, Pilling, Right Line, Right Patient, Right Time, Rusch and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks of their respective owners.
© 2016 Teleflex Incorporated. All rights reserved. MC-002544

Rx Only

Chlorag+ard® Technology is contraindicated for patients with known hypersensitivity to chlorhexidine.


  1. Data on file. As compared to uncoated catheters, intravascular ovine model inoculated with Staph aureus. No correlation between in vitro / in vivo testing methods and clinical outcomes have currently been ascertained.
  2. In vitro data on file 2010. No correlation between in vitro / in vivo testing methods and clinical outcomes have currently been ascertained.

View source version on

Business Wire

Last updated on: 16/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.